Skip to main content

Alkermes plc.

corporate_fare Company Profile

Alkermes plc.

ALKS·NASDAQ·Life Sciences·CIK 0001520262

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. It also maintains a pipeline of clinical and preclinical candidates for neurological disorders. Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts, and a manufacturing facility in Ohio. On February 12, 2026, Alkermes completed the acquisition of Avadel Pharmaceuticals plc, adding LUMRYZ to its proprietary commercial products and gaining a commercial organization experienced in narcolepsy. The acquisition involved consideration of $21.00 per Avadel ordinary share in cash at closing, plus a non-transferable contingent value right for a potential additional cash payment of $1.50 per Avadel share upon achieving a specified milestone. Alkermes' proprietary commercial products include treatments for schizophrenia, narcolepsy, bipolar I disorder, alcohol dependence, and opioid dependence in the U.S. Additionally, the company licenses its proprietary technologies for key third-party products. For example, RISPERDAL CONSTA, indicated for schizophrenia and bipolar I disorder, is commercialized by Janssen Pharmaceuticals, Inc. in a licensed territory.

Alkermes plc. (NASDAQ:ALKS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ALKS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ALKS spans 8-K, 10-Q, 8-K/A, DEF 14A.

Recent high-impact activity:

  • Alkermes Settles Teva LYBALVI Patent Suit; Generic Entry Delayed to November 2039
  • Alkermes 10-Q: Q3 Revenue Up 22% to $480M, but Nine-Month Swing to $49.7M Loss
  • Alkermes Posts Q3 2026 Results, Call Set for 8:00 a.m. ET
  • Alkermes' ALKS 7290 Shows Clinically Meaningful ADHD Symptom Improvement in Phase 1b
  • Alkermes Details $8M Equity Package for Incoming CEO Blair Jackson, Adds President Title and Board Seat

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.48B
Net Income
$241.66M
Diluted EPS
$1.43
Op. Cash Flow
$520.75M
Free Cash Flow
$480.33M
Gross Profit
$1.28B
Operating Income
$253.96M
Cash & Equivalents
$388.57M
Debt / Equity
0.00×
Net Margin
16.4%
Shares Outstanding
165.61M sh
Source: 10-K · filed 2026-02-25 · accession 0001193125-26-068925

Short Interest & Short Volume

11.25 days to cover

FINRA reported short interest of 19,647,994 shares in ALKS as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 11.3 days to cover at its recent average daily volume. On November 20, 2026, 67.0% of ALKS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,647,994 shares as of October 30, 2026
Change vs prior period▲ 3.2%
Days to cover11.25 at avg daily volume of 1,746,478
Daily short volume (FINRA facilities)67.0% of 280,881 shares on November 20, 2026
5-day average short volume63.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$45.5 +1.25% today
52-week range · as of 2026-11-12 $27 – $55.67
Market cap
$7.55B
Volume
1.1M (0.6× avg)
3-mo avg 1.7M
Live data · 2026-11-22 03:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALKS - Latest Insights

ALKS
Nov 12, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.69
Real-time Price: $45.50 info
Change: -$2.19 (-5%) info
Market Cap: $7.552B info
ALKS
Nov 03, 2026, 9:20 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $45.50 info
Change: +$0.150 (+0.33%) info
Market Cap: $7.552B info
ALKS
Nov 03, 2026, 7:05 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.50
Real-time Price: $45.50 info
Change: $0 (0%) info
Market Cap: $7.552B info
ALKS
Sep 21, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.45
Real-time Price: $45.50 info
Change: +$2.05 (+5%) info
Market Cap: $7.552B info
ALKS
Aug 03, 2026, 4:08 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $49.53
Real-time Price: $45.50 info
Change: -$4.03 (-8%) info
Market Cap: $7.552B info
ALKS
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $49.51
Real-time Price: $45.50 info
Change: -$4.01 (-8%) info
Market Cap: $7.552B info
ALKS
Jul 28, 2026, 9:22 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $49.00
Real-time Price: $45.50 info
Change: -$3.50 (-7%) info
Market Cap: $7.552B info
ALKS
Jul 28, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $51.79
Real-time Price: $45.50 info
Change: -$6.29 (-12%) info
Market Cap: $7.552B info
ALKS
Jul 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $55.36
Real-time Price: $45.50 info
Change: -$9.86 (-18%) info
Market Cap: $7.552B info
ALKS
Jun 17, 2026, 4:21 PM EDT
Source: Binance News
Importance Score:
8
Price at Filing: $44.09
Real-time Price: $45.50 info
Change: +$1.41 (+3%) info
Market Cap: $7.552B info
ALKS
Jun 15, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.60
Real-time Price: $45.50 info
Change: +$0.900 (+2%) info
Market Cap: $7.552B info
ALKS
May 20, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.10
Real-time Price: $45.50 info
Change: +$8.40 (+23%) info
Market Cap: $7.552B info
ALKS
May 12, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.67
Real-time Price: $45.50 info
Change: +$9.83 (+28%) info
Market Cap: $7.552B info
ALKS
May 05, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.64
Real-time Price: $45.50 info
Change: +$8.86 (+24%) info
Market Cap: $7.552B info
ALKS
May 05, 2026, 7:07 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $45.50 info
Change: +$10.52 (+30%) info
Market Cap: $7.552B info
ALKS
May 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.15
Real-time Price: $45.50 info
Change: +$10.35 (+29%) info
Market Cap: $7.552B info
ALKS
May 01, 2026, 4:51 PM EDT
Filing Type: 8-K/A
Importance Score:
9
Price at Filing: $33.38
Real-time Price: $45.50 info
Change: +$12.12 (+36%) info
Market Cap: $7.552B info
ALKS
Apr 06, 2026, 5:04 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $34.26
Real-time Price: $45.50 info
Change: +$11.24 (+33%) info
Market Cap: $7.552B info
ALKS
Mar 27, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $29.39
Real-time Price: $45.50 info
Change: +$16.11 (+55%) info
Market Cap: $7.552B info
ALKS
Feb 25, 2026, 9:31 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.41
Real-time Price: $45.50 info
Change: +$13.09 (+40%) info
Market Cap: $7.552B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets